833 related articles for article (PubMed ID: 30590440)
1. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP
Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440
[TBL] [Abstract][Full Text] [Related]
2. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
5. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
[TBL] [Abstract][Full Text] [Related]
6. Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
Kwon S; Lee SR; Choi EK; Choe WS; Lee E; Jung JH; Han KD; Oh S; Lip GYH
Am Heart J; 2020 Nov; 229():81-91. PubMed ID: 32927313
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
8. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.
Schäfer A; Flierl U; Berliner D; Bauersachs J
Cardiovasc Drugs Ther; 2020 Aug; 34(4):555-568. PubMed ID: 32350792
[TBL] [Abstract][Full Text] [Related]
10. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
11. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Weitz JI; Eikelboom J
Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
[TBL] [Abstract][Full Text] [Related]
12. Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis.
Huang WY; Singer DE; Wu YL; Chiang CE; Weng HH; Lee M; Ovbiagele B
JAMA Neurol; 2018 Dec; 75(12):1511-1518. PubMed ID: 30105396
[TBL] [Abstract][Full Text] [Related]
13. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
14. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
15. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
[TBL] [Abstract][Full Text] [Related]
16. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
[TBL] [Abstract][Full Text] [Related]
17. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
18. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis.
Malhotra K; Ishfaq MF; Goyal N; Katsanos AH; Parissis J; Alexandrov AW; Alexandrov AV; Tsivgoulis G
Neurology; 2019 May; 92(21):e2421-e2431. PubMed ID: 31068485
[TBL] [Abstract][Full Text] [Related]
19. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Liu X; Huang M; Ye C; Zeng J; Zeng C; Ma J
Medicine (Baltimore); 2020 Jul; 99(27):e21025. PubMed ID: 32629725
[TBL] [Abstract][Full Text] [Related]
20. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]